AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Sep - Notice of 22nd AGM of the company to be held 30th September, 2026 through VC/OCAM published in Newspaper.
Source: Bse
Indo Us Biotech Limited (INDOUS)
Small CapPharma stocks · Small cap · NSE
Indo Us Biotech Limited operates in Seeds & Biotech, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals06 Oct 2026 · screener
Latest result12 Aug, 03:34 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
52Neutralfull bear SMA stack · SMA20 -5.6% / mo · RSI oversold · MACD − · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
INDOUSD candles · FIT view-30.5%Latest close ₹71.28 on 2026-10-19
Bar
-4.2%
RSI
30
MACD hist
-0.27
52W pos
1%
2026-10-19O ₹74.40H ₹74.40L ₹71.22C ₹71.28Vol 5,484 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
INDOUSNifty PharmaNifty 500
- INDOUS
- -18.4%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -12.8 pp
Chart stats
19 Oct 2026- From 52W high
- -55.2%
- 52W range position
- 1%
- ATR (14)
- 5.5%
- Volume vs 20D
- 0.83x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹70.3 - ₹82.8
₹159
₹70 - ₹159
₹3.9
Latest completed session
20-session average
18.8% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST42
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +7.2% · PAT -35.3% YoY
Technical
Neutral52
Price trend and sector-relative-strength timing.
Valuation
Legacy model+42.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence60
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100PAT -35% YoY · margin compression · Rev +7% YoY · +27% QoQ
Filed 12 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹33 Cr | +7.2% | +26.8% |
| EBITDA | ₹4 Cr | -27.4% | +22.9% |
| Operating margin | 12.0% | -575 bps | -38 bps |
| PAT | ₹3 Cr | -35.3% | +54.3% |
| PAT margin | 9.2% | -606 bps | +164 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 29.90
- P/B
- 3.60
- EV/EBITDA
- 22.60
- Market Cap
- 151.00Cr
Profitability
- ROE
- 16.90%
- ROCE
- 15.40%
- ROA
- 9.10%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 16.00%
- EPS 5Y
- 16.00%
- Revenue 3Y
- -32.00%
- EPS 3Y
- -32.00%
Balance Sheet
- Debt/Equity
- 0.33
- Interest Coverage
- 5.66×
- Altman Z
- 7.57
- Book Value
- 21.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- 2.70 Cr
- EPS TTM
- 2.77
Shareholding
- Promoter Hold
- 68.29%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 6%
Financial History
Updated 18/10/2026
Revenue
₹ CrLatest: 33.0+26.8% vs prev
Net Profit
₹ CrLatest: 3.0+54.3% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 30. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~5.9% over last month) — short-term momentum negative.
- RSI(14) at 30 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
7
RS percentile
Stage 4 Downtrend
1M return
-8.6%
3M return
-18.4%
6M return
-33.3%
1Y return
-49.7%
RS 1D
0
RS 20D
-1
Sector rank
#1
Industry rank
#65
Stage evidence
- Price is 21.4% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -6.5%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
improving
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 54.23+0.09%
RS vs Nifty 50054
Valuation & peers
U-Score 42 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 42 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation11/30
Growth12/25
Quality11/20
Balance Sheet9/15
Cash Flow1/10
Piotroski
8/9 (+5)
Penalties
-7
Raw sum
42
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
42/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 42.8%.
- Balance sheet contributes 9/15 to the score.
Main drags
- Penalty bucket subtracts 7 points.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
- Valuation is weaker at 11/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
29.9
PB
3.6
EV/EBITDA
22.6
ROE
16.9%
ROCE
15.4%
FCF Yield
—
Debt/Equity
0.3
MoS
+42.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
42
Previous: 42
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+42.8%
Previous: +42.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
41
41
41
41
41
42
42
41
41
42
42
42
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹36.18
-97.0% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹124.65
+42.8% MoS
PEG
1.87
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
AJOONI
Small
Ajooni Biotech Limited
Biotechnology
match 136
56
13.5
4.3%
+72%
FAIR VALUE
NATHBIOGEN
Small
Nath Bio-Genes (India) Limited
Biotechnology
match 132
35
7.7
5.3%
-124%
WATCHLIST
SHEEL
SME
Sheel Biotech Ltd.
Biotechnology
match 131
60
10.4
11.2%
+76%
UNDERVALUED
HESTERBIO
Small
Hester Biosciences Limited
Biotechnology
match 121
57
33.7
15.9%
+28%
FAIR VALUE
BIOCON
Mid
Biocon Limited
Biotechnology
match 115
32
78.9
1.4%
-2833%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Indo Us Biotech Limited operates in Seeds & Biotech, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
60Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 28th percentile of the scored universe and 19th percentile within Pharma. Main check: results consistency is weak at 27/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
5 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
28th percentile
overall median 67 · Pharma: 19th pctile, median 70 · Small: 32nd pctile, median 66
Evidence depth
Financial-only
5 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
27
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 68.3%.
- ▸Promoter pledge is zero.
Trust risks
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸Promoter holding fell 1.9%.
- ▸Only 0 years of positive FCF.
- ▸0/4 latest quarters had positive YoY PAT growth.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Indo Us Biotech Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual report
Reg. 34 (1) Annual Report. 5 Sep
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Jul - Postal Ballot Notice dated 4th July, 2026 published in Western times English and Gujarati Newspaper.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Aug - Submitting Newspaper Advertisement relating to the Unaudited Quarterly Standalone Financial Results for the quarter ended on 30th June, 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Revised: Additional Details Required For Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations, 2015. Ref.: Mail From [email protected] On 13.07.2026 Subject: Resignation Of Statutory Auditor And Appointment Of New Statutory Auditor. Resubmitting The Details As Per Attached SEBI Circular Dated October 18, 2019, Through BSE Listing Centre. 15 Jul - Gautam N Associates resigned effective 15 June 2026; Bhagat & Associates appointed, pending shareholder approval.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement Under Regulation 30 Of SEBI LODR (Resignation Of Existing Statutory Auditor, Appointment Of New Statutory Auditor, Resignation Of Existing Internal Auditor And Appointment Of New Internal Auditor) 16 Jun - Board approved statutory and internal auditor changes effective 16 June 2026.
Source: Bse
Announcement
Revised: Additional Details Required For Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations, 2015. Ref.: Mail From [email protected] At 11:00?AM On 17.06.2026 Subject: Resignation Of Statutory Auditor And Appointment Of New Statutory Auditor. 17 Jun - Gautam N Associates resigned as auditor; Bhagat & Associates appointed subject to shareholder approval.
Source: Bse
AnnouncementApr 2026
Apr 2026 · Resignation Of Mrs. Nehaben Sachinbhai Patel (DIN: 09263180) From The Post Of Independent Director Of The Company. 21 Apr - Mrs. Nehaben Sachinbhai Patel resigned as Independent Director effective 21 April 2026.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.